Clinical trials: Advanced Solid Malignancy, open to volunteers
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
The main purpose of this study is to evaluate the safety and tolerability of almonertinib combined with palbociclib in patients with advanced solid tumors harboring KRAS gene mutations, and to conduct a preliminary observation of…
- Trial name
- APEAK (NCT06947811)
- Testing
- Almonertinib, Palbociclib
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Sun Yat-sen University
Solid Tumours
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given…
- Trial name
- NCT07165067
- Testing
- AP601
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- AP Biosciences Inc.
Solid Tumor, Lymphoma
Intratumoral CAN2109 in Subjects With Solid Tumors
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
- Trial name
- NCT06332430
- Testing
- CAN2109
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Canwell Biotech Limited
Advanced Solid Tumor
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
- Trial name
- NCT06859762
- Testing
- YL217, Bevacizumab, 5-FU with leucovorin
- Where
- 21 sites in United States, China
- Volunteers
- 630 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Solid Tumors
A Study of HS-20110 in Participants With Advanced Solid Tumors
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
- Trial name
- NCT06892379
- Testing
- HS-20110 (Phase Ia：Dose escalation ), HS-20110 (Phase Ib:Dose expansion )
- Where
- 8 sites in United States, China
- Volunteers
- 475 people
- Sponsor
- Hansoh BioMedical R&D Company
Solid Tumor
SB17170 Phase 1 Clinical Trial in Solid Tumors
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
- Trial name
- NCT05522868
- Testing
- SB17170
- Where
- 3 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- SPARK Biopharma
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.
- Trial name
- NCT06947291
- Testing
- Glumetinib Tablets, Docetaxel for Injection (Albumin-bound)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer.
- Trial name
- NCT06084286
- Testing
- Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Advanced Malignant Solid Tumor
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07045454
- Testing
- MHB118C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Tumor
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab…
- Trial name
- NCT05761223
- Testing
- Phase Ia dose-escalation part of FB849 Monotherapy, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- 1ST Biotherapeutics, Inc.
Solid Tumor
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid…
- Trial name
- NCT06016062
- Testing
- RC148 Monotherapy, RC148+docetaxel Combination Therapy, RC148+RC48 Combination Therapy
- Where
- 31 sites in China
- Volunteers
- 221 people
- Sponsor
- RemeGen Co., Ltd.
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
- Trial name
- NCT07158918
- Testing
- ABL103, KEYTRUDA® (pembrolizumab), Taxane
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 65 people
- Sponsor
- ABL Bio, Inc.
KRAS G12C Mutation Advanced Solid Tumor
Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.
This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in…
- Trial name
- NCT07615413
- Testing
- HS-10541
- Volunteers
- 636 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer, Colon Cancer
A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer
This is a first-in-human Phase 1 study of DEM301 in adults with previously treated advanced metastatic colorectal cancer. DEM301 is an investigational antibody-drug conjugate.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT07805369
- Testing
- DEM301
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- DEM BioPharma, Inc.
Advanced Malignant Solid Tumors
SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced…
- Trial name
- NCT07665970
- Testing
- SCTB41+SCTB39G
- Volunteers
- 112 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumors
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the…
- Trial name
- NCT06520488
- Testing
- HRS-4642
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Protocol Title: Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with…
- Trial name
- ASCENT-1 (NCT07751042)
- Testing
- STX-003, KEYTRUDA®
- Where
- 4 sites in United States, Australia
- Volunteers
- 220 people
- Sponsor
- Strand Therapeutics Inc.
Malignant Tumor
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
Advanced solid tumors remain a major therapeutic challenge due to their complex heterogeneity and the immunosuppressive tumor microenvironment (TME).
- Trial name
- NCT07567222
- Testing
- YMN101, YMN102, YMN103
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- West China Hospital
Solid Tumors
A Phase 1 Study of HDM2017 in Advanced Solid Tumors
This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor…
- Trial name
- NCT07274085
- Testing
- HDM2017
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.